NTRA
Natera Inc

2,269
Mkt Cap
$26.76B
Volume
936,886.00
52W High
$196.63
52W Low
$117.27
PE Ratio
-102.56
NTRA Fundamentals
Price
$195.00
Prev Close
$188.02
Open
$187.16
50D MA
$170.51
Beta
1.28
Avg. Volume
1.08M
EPS (Annual)
-$1.53
P/B
21.40
Rev/Employee
$382,704.33
Loading...
Loading...
News
all
press releases
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
Natera Named to Fast Companys Next Big Things in Tech List
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named to Fast Companys 2025 Next Big Things in Tech list. Honored for its...
Business Wire·8d ago
News Placeholder
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m...
Business Wire·11d ago
News Placeholder
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical...
Business Wire·11d ago
News Placeholder
Signatera Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in...
Business Wire·2mo ago
News Placeholder
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.
Zacks·2mo ago
News Placeholder
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3mo ago
News Placeholder
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of -23.33% and +15.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Pediatrix Medical Group (MD) Q2 Earnings and Revenues Top Estimates
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of +26.19% and +0.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates
Medpace (MEDP) delivered earnings and revenue surprises of +3.33% and +11.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest NTRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.